8- dioxa- 11- azadispiro(2.0.4.3)undec- 11- yl)ethoxy)- 7- methoxy- 4- quinazolinamine N-(3-chloro-4-fluorophenyl)-6-(2-(5

an epidermal growth factor receptor tyrosine kinase inhibitor; structure in first source

Also Known As:

N-(3-chloro-4-fluorophenyl)-6-(2-(5, 8-dioxa-11-azadispiro(2.0.4.3)undec-11-yl)ethoxy)-7-methoxy-4-quinazolinamine; simotinib

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/01/2014 - "The method is now used to support clinical pharmacokinetic studies in patients with non-small cell lung cancer (NSCLC) after oral administration of simotinib." 01/01/2019 - "Purpose: The aim of this phase Ib study (clinicaltrials.gov: NCT01772732) was to assess safety, tolerability, and pharmacokinetics (PKs) of simotinib (a novel EGFR tyrosine kinase inhibitor) in patients with advanced non-small cell lung cancer (NSCLC) and EGFR gene mutation. " 01/01/2019 - "Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial."
2.	Neoplasms (Cancer) 01/01/2014 - "Simotinib hydrochloride (SIM6802), which is a new epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is often prescribed for cancer patients with comorbidities and has serious adverse effects on gastrointestinal physiology. "

1.	Oral Administration